Abstract
Background
Chemotherapeutic agents are classified by their degree of emetogenicity. Highly and moderately emetogenic agents require antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. Intravenous etoposide is listed as having low emetic potential. However, oral etoposide is categorized as having moderate emetogenicity. Daily oral etoposide is used in refractory germ cell cancer patients. We prospectively evaluated the emetic potential of oral etoposide in this patient population.
Materials and methods
Between August 2003 and February 2006, 16 patients with refractory germ cell cancer received single-agent, daily oral etoposide 50 mg/M2 for 21 consecutive days every 4 weeks. All patients had progressed after cisplatin combination chemotherapy and had received high-dose chemotherapy with carboplatin plus etoposide (intravenously) with peripheral blood stem cell transplant. No patient received prophylactic antiemetics. Patients completed a six-question Multinational Association of Supportive Care in Cancer (MASCC) antiemetic tool during each day of etoposide during the first 21-day course. Nausea intensity and duration were recorded. Number of emetic episodes and any antiemetic medications were recorded.
Results
All 16 patients completed the six-question MASCC form. Eleven of 16 had no nausea or vomiting and two other patients had only minimal nausea, despite absence of any prophylactic antiemetics. Only two patients required antiemetic support. Two patients experienced emesis for a single episode. One patient had nausea on days 9–20 with a MASCC rating of 3–6, and one patient had continued mild nausea (MASCC rating 1–3) for all 21 days.
Conclusions
Daily oral etoposide has a low probability of producing chemotherapy-induced nausea and/or vomiting and, in our opinion, does not require prophylactic antiemetics.
References
Bhatia S, Abonour R, Porcu P et al (2000) High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346–3351
Cooper MA, Einhorn LH (1995) Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 13:1167–1169
Einhorn LH (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731–735
Einhorn LH (2002) Curing cancer: testicular cancer. Proc Natl Acad Sci U S A 99:4592–4595
Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994
Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84
Herrstedt J, Koeller JM, Roila F et al (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:97–103
Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109
Miller JC, Einhorn LH (1990) Phase II study of daily oral etoposide is refractory germ cell tumors. Semin Oncol 17:36–39
Roila F, Warr D, Clark-Snow RA et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104–108
Ross W, Rowe T, Glisson B et al (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44:5857–5860
Vardy JL, Chiew K, Galica J, Pond GR, Tannock IF (2005) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011–1015
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Einhorn, L.H., Brames, M.J. Emetic potential of daily oral etoposide. Support Care Cancer 14, 1262–1265 (2006). https://doi.org/10.1007/s00520-006-0106-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-006-0106-x